Pharsight

Drugs that contain Ibrexafungerp Citrate

1. Brexafemme patents expiration

BREXAFEMME's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8188085 SCYNEXIS Antifungal agents
Aug, 2030

(6 years from now)

US10174074 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(10 years from now)

US10927142 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(10 years from now)

US11534433 SCYNEXIS Antifungal agents with enhanced activity in acidic pH
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2026
New Indication (I) Nov 30, 2025
Generating Antibiotic Incentives Now (GAIN) Jun 1, 2031

NCE-1 date: 2030-06-01

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatr...

Dosage: TABLET;ORAL

More Information on Dosage

BREXAFEMME family patents

Family Patents